参考文献/References:
[1] Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a "state of the science" [J]. Neuro Oncol, 2014, 16(7) : 896-913.
[2] Bush NA, Chang SM, Berger MS. Current and future strate-gies for treatment of glioma [J]. Neurosurg Rev, 2017, 40(1): 1-14.
[3] 杜 霞，刁 波. 多形性胶质母细胞瘤的免疫治疗[J]. 中国临床神经外科杂志，2017，22（7）：514-516.
[4] Louveau A, Smirnov I, Keyes TJ, et al. Structural and func-tional features of central nervous system lymphatic vessels [J]. Nature, 2015, 523(7560): 337-341.
[5] Tu M, Wange W, Cai L, et al. IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway [J]. Tumour Biol, 2016, 37(11): 14701-14709.
[6] Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma [J]. Clin CancerRes, 2015, 21(18): 4062-4072.
[7] Brown CE, Aguilar B, Starr R, et al. Optimization of IL13Rα2- targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma [J]. Mol Ther,2018, 26(1): 31-44.
[8] Brown CE, Alizadeh D, Starr R, et al. Regression of gliob-lastoma after chimeric antigen receptor T-cell therapy [J]. N Engl J Med, 2016, 375(26): 2561-2569.
[9] Keu KV, Witney TH, Yaghoubi S, et al. Reporter gene imag-ing of targeted T cell immunotherapy in recurrent glioma [J].Sci Transl Med, 2017, 9(373): 2196-2203.
[10] Villa GR, Mischel PS. Old player, new partner: EGFRVⅢ and cytokine receptor signaling in glioblastoma [J]. Nat Neurosci, 2016, 19(6): 765-767.
[11] Morgan RA, Johnson LA, Davis JL, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRVⅢ and development of adoptive cell therapy for glioma [J]. Hum Gene Ther, 2012, 23(10): 1043-1053.
[12] Miao H, Choi BD, Suryadevara CM, et al. EGFRVⅢ-speci-fic chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an inva-sive xenograft model of glioblastoma [J]. PLoS One, 2014, 9(4): 281-287.
[13] 郑 岩，谢甲贝，曹名波，等. EGFRvⅢ/CAR-T对EGFRvⅢ+ U87胶质瘤细胞和裸鼠移植瘤的特异性杀伤作用[J]. 中国肿瘤生物治疗杂志，2018，25（4）：334-339.
[14] O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRVⅢ-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma [J]. Sci Transl Med, 2017, 9(399): 984-989.
[15] Felsberg J, Hentschel B, Kaulich K, et al. Epidermal growth factor receptor variantⅢ (EGFRVⅢ) positivity in egframp-lified glioblastomas: prognostic role and comparison between primary and recurrent tumors [J]. Clin Cancer Res, 2017, 23(22): 6846-6855.
[16] Rui Liu, Qu YP, Chen LH, et al. Genomic copy number gains of ErbB family members predict poor clinical out-comes in glioma patients [J]. Oncotarget, 2017, 8(54): 92275-92288.
[17] Morgan RA, Yang JC, Kitano M, et al. Case report of a seri-ous adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 [J]. Mol Ther, 2010, 18: 843-851.
[18] Ahmed N, Salsman VS, Kew Y, et al. HER2-specific T cellstarget primary glioblastoma stem cells and induce regressionof autologous experimental tumors [J]. Clin Cancer Res, 2010, 16(2): 474-485.
[19] Ahmed N, Brawley V, Hegde M, et al. HER2-specific chi-meric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial [J].JAMA Oncol, 2017, 3(8): 1094-1101.
[20] Hui M, Nickolas W, Hong G, et al. EphA2 promotes infil-trative invasion of glioma stem cells in vivo through cross-talk with akt and regulates stem properties [J]. Oncogene, 2015, 34(5): 558-567.
[21] Chow KK, Naik S, Kakarla S, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma[J]. Mol Ther,2013, 21(3): 629-637.
[22] Yi ZZ, Prinzing BL, Cao F, et al. Optimizing EphA2-CAR T Cells for the adoptive immunotherapy of glioma [J]. Mol Ther Methods Clin Dev, 2018, 9: 70-80.
[23] Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cellstargeting HER2 and IL13Rα2 mitigate tumor antigen escape[J]. J Clin Invest, 2016, 126(8): 3036-3052.
[24] Bielamowicz K, Fousek K, Byrd TT, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblas-toma [J]. Neuro-Oncology, 2018, 20(4): 506-518.
[25] 赵炜熠，初 明. 胶质瘤免疫抑制与治疗的研究进展[J]. 中国临床神经外科杂志，2018，23（3）：212-214.
[26] Zheng Y, Gao N, Fu YL, et al. Generation of regulable EGFRVⅢ targeted chimeric antigen receptor T cells for adoptive cell therapy of glioblastoma [J]. Biochem Biophys Res Commun, 2018, 507(1-4): 59-66.
相似文献/References:
[1]谢宝树 张 林 王 宇 贾 锋 殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(01):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述 高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强 杨吉安 邵灵敏 吴庭枫 刘宝辉 陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(01):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇 冯 军 黄俊红 白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(01):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕 孟凡华 刘魏然 魏春晓 林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元 王汉东 樊友武 贾 玥 吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(01):69.
[7]郑锐哲 姜秀峰 陈二涛 孙兆良 冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(01):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]殷安安 陆 南 贺亚龙 章 翔 刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(01):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[10]吴 蛟 易 勇 赵卓琳 周良学 周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(01):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]